Ishimoto AK, Shah AA (2024) Screening and early treatment for osteoporosis: who are we missing under age 65? Maturitas 187:108044
Article PubMed CAS Google Scholar
Taher AT, Musallam KM, Cappellini MD (2021) β-Thalassemias. Longo DL, editor. N Engl J Med.;384(8):727–43
Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2005) Survival and complications in Thalassemia. Ann N Y Acad Sci 1054:40–47
Article PubMed CAS Google Scholar
Tuo Y, Li Y, Li Y et al (2024) Global, regional, and national burden of Thalassemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine 72:102619
Article PubMed PubMed Central Google Scholar
Bhardwaj A, Swe KMM, Sinha NK, Osunkwo I (2016) Treatment for osteoporosis in people with ß-thalassaemia. Cochrane Database Syst Rev 3:CD010429
Di Paola A, Marrapodi MM, Di Martino M et al (2024) Bone Health Impairment in patients with hemoglobinopathies: from Biological bases to New possible therapeutic strategies. Int J Mol Sci 25(5):2902
Article PubMed PubMed Central Google Scholar
Baldini M, Forti S, Marcon A, Ulivieri FM, Orsatti A, Tampieri B et al (2010) Endocrine and bone disease in appropriately treated adult patients with beta-thalassemia major. Ann Hematol 89(12):1207–1213
Article PubMed CAS Google Scholar
Canatan D (2013) The Thalassemia Center of Antalya State Hospital: 15 years of experience (1994 to 2008). J Pediatr Hematol Oncol 35(1):24–27
Leung TF, Chu Y, Lee V, Cheng FWT, Leung WK, Shing MMK et al (2009) Long-Term effects of Pamidronate in Thalassemic patients with severe bone Mineral Density deficits. Hemoglobin 33(5):361–369
Article PubMed CAS Google Scholar
Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N et al (2009) Bone disease in Thalassemia: a frequent and still unresolved problem. J Bone Miner Res 24(3):543–557
Kyriakou A, Savva SC, Savvides I, Pangalou E, Ioannou YS, Christou S et al (2008) Gender differences in the prevalence and severity of bone disease in Thalassaemia. Pediatr Endocrinol Rev 6(Suppl 1):116–122
Fung EB, Harmatz PR, Milet M, Coates TD, Thompson AA, Ranalli M et al (2008) Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 43(1):162–168
Article PubMed PubMed Central CAS Google Scholar
Vogiatzi MG, Macklin EA, Fung EB, Vichinsky E, Olivieri N, Kwiatkowski J et al (2006) Prevalence of fractures among the thalassemia syndromes in North America. Bone 38(4):571–575
Article PubMed CAS Google Scholar
Engkakul P, Mahachoklertwattana P, Jaovisidha S, Chuansumrit A, Poomthavorn P, Chitrapazt N et al (2013) Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 35(3):212–217
Cooper C, Dennison EM, Leufkens HG, Bishop N, Van Staa TP (2004) Epidemiology of Childhood fractures in Britain: a study using the General Practice Research Database. J Bone Min Res 19(12):1976–1981
Chen YG, Lu CS, Lin TY, Lin CL, Tzeng HE, Tsai CH (2018) Risk of fracture in transfusion-naïve thalassemia population: a nationwide population-based retrospective cohort study. Bone 106:121–125
Yang R, Zou X, Zeng H, Zhao Y, Ma X (2020) Comparison of diagnostic performance of five different Ultrasound TI-RADS classification guidelines for thyroid nodules. Front Oncol 10:598225
Article PubMed PubMed Central Google Scholar
Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Strauss BJ, Bowden D et al (2013) Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int 24(7):1965–1971
Article PubMed CAS Google Scholar
Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D’Amore M (2009) Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with Thalassaemia major. Panminerva Med 51(1):17–23
Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M et al (2004) Osteoprotegerin and RANKL in the Pathogenesis of Thalassemia-Induced osteoporosis: New Pieces of the Puzzle. J Bone Min Res 19(5):722–727
Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA et al (2013) Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 382(9886):50–56
Article PubMed PubMed Central CAS Google Scholar
Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis A, Komninaka V et al (2012) High circulating sclerostin is Present in patients with thalassemia-associated osteoporosis and correlates with bone Mineral Density. Horm Metab Res 44(12):909–913
Article PubMed CAS Google Scholar
Sapunarova K, Goranova-Marinova V, Georgiev P, Deneva T, Tsvetkova S, Grudeva-Popova Z (2020) Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia. Ann Med 52(3–4):94–108
Article PubMed PubMed Central CAS Google Scholar
Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Dimopoulou M, Komninaka V, Repa K et al (2019) Activin-A is elevated in patients with Thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density. Ann Hematol 98(7):1583–1592
Article PubMed CAS Google Scholar
Singh K, Kumar R, Shukla A, Phadke SR, Agarwal S (2012) Status of 25-hydroxyvitamin D deficiency and effect of vitamin D receptor gene polymorphisms on bone mineral density in Thalassemia patients of North India. Hematology 17(5):291–296
Article PubMed CAS Google Scholar
Arisal O, Deviren A, Fenerci EY, Hacihanefioglu S, Ulutin T, Erkmen S et al (2002) Polymorphism analysis in the COLIA1 gene of patients with Thalassemia major and intermedia. Haematologia (Budap) 32(4):475–482
Dimitriadou M, Christoforidis A, Fidani L, Economou M, Perifanis V, Tsatra I et al (2011) Fok-I gene polymorphism of vitamin D receptor in patients with beta‐thalassemia major and its effect on vitamin D status. Hematology 16(1):54–58
Article PubMed CAS Google Scholar
Langdahl G, Brixen E (2000) Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures: VDR polymorphisms and osteoporosis. Eur J Clin Invest 30(7):608–617
Article PubMed CAS Google Scholar
Ferrara M, Matarese SMR, Francese M, Borrelli B, Coppola A, Coppola L et al (2002) Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia: short report. Br J Haematol 117(2):436–440
Article PubMed CAS Google Scholar
Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D’Agruma L et al (2000) Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 111(2):461–466
Ragab SM, Badr EA, Ibrahim AS (2016) Evaluation of Glutathione-S-Transferase P1 polymorphism and its relation to bone Mineral Density in Egyptian Children and adolescents with Beta-Thalassemia Major. Mediterr J Hematol Infect Dis 8(1):e2016004
Article PubMed PubMed Central Google Scholar
Yavropoulou MP, Anastasilakis AD, Tzoulis P, Tournis S, Rigatou E, Kassi E et al (2022) Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited: osteoporosis in β-thalassemia major. Acta Biomed Atenei Parmensis 93(5):e2022305
Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JCG et al (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J bone Mineral Research: Official J Am Soc Bone Mineral Res 29(11):2468–2473
Comments (0)